Samuel Moix

Samuel Moix

Auto-generated profile, based on publicly available information

Samuel Moix

Department of Computational Biology, UNIL, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Genome Biology
Verified
Journal Article
Open access
PDF file
SMSamuel Moix
Samuel Moix
MSMarie C Sadler
Marie C Sadler
ZKZoltán Kutalik
Zoltán Kutalik
CAChiara Auwerx
Chiara Auwerx
Background: Telomeres form repeated DNA sequences at the ends of chromosomes, which shorten with each cell division. Yet, factors modulating telomere attrition and the health consequences thereof are not fully understood. To address this, we leveraged data from 326,363 unrelated UK Biobank participants of European ancestry. Results: Using linear regression and bidirectional univariable and multivariable Mendelian randomization (MR), we elucidate the relationships between leukocyte telomere length (LTL) and 142 complex traits, including diseases, biomarkers, and lifestyle factors. We confirm that telomeres shorten with age and show a stronger decline in males than in females, with these factors contributing to the majority of the 5.4% of LTL variance explained by the phenome. MR reveals 23 traits modulating LTL. Smoking cessation and high educational attainment associate with longer LTL, while weekly alcohol intake, body mass index, urate levels, and female reproductive events, such as childbirth, associate with shorter LTL. We also identify 24 traits affected by LTL, with risk for cardiovascular, pulmonary, and some autoimmune diseases being increased by short LTL, while longer LTL increased risk for other autoimmune conditions and cancers. Through multivariable MR, we show that LTL may partially mediate the impact of educational attainment, body mass index, and female age at childbirth on proxied lifespan. Conclusions: Our study sheds light on the modulators, consequences, and the mediatory role of telomeres, portraying an intricate relationship between LTL, diseases, lifestyle, and socio-economic factors.

21 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CAChiara Auwerx
Chiara Auwerx
SMSamuel Moix
Samuel Moix
ZKZoltán Kutalik
Zoltán Kutalik
ARAlexandre Reymond
Alexandre Reymond
Whereas 16p11.2 BP4-5 copy-number variants (CNVs) represent one of the most pleiotropic etiologies of genomic syndromes in both clinical and population cohorts, the mechanisms leading to such pleiotropy remain understudied. Identifying 73 deletion and 89 duplication carriers among unrelated white British UK Biobank participants, we performed a phenome-wide association study between the region’s copy number and 117 complex traits and diseases, mimicking four dosage models. Forty-six phenotypes (39%) were affected by 16p11.2 BP4-5 CNVs, with the deletion-only, mirror, U-shape, and duplication-only models being the best fit for thirty, ten, four, and two phenotypes, respectively, aligning with the stronger deleteriousness of the deletion. Upon individually adjusting CNV effects for either body mass index (BMI), height, cognitive function, or socio-economic status as potential mediators, we found that sixteen testable deletion-driven associations (61%) – primarily with cardiovascular and metabolic traits – were BMI-dependent, with other mediators playing a more subtle role. Bidirectional Mendelian randomization supported that 13 out of these 16 associations (81%) were secondary consequences of the CNV’s impact on BMI. For the 22 traits that remained significantly associated upon individual adjustment for mediators, matched-control analyses found that eleven phenotypes, including musculoskeletal traits, liver enzymes, fluid intelligence, platelet count, pulmonary capacity, pneumonia, and acute kidney injury, remained associated under strict Bonferroni correction, with eight additional nominally significant associations. These results paint a complex picture of 16p11.2 BP4-5’s pleiotropic pattern that involves direct effects on multiple physiological systems and indirect co-morbidities consequential to the CNV’s impact on BMI and cognition, acting through trait-specific dosage mechanisms.

13 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SMSamuel Moix
Samuel Moix
MSMarie Sadler
Marie Sadler
ZKZoltán Kutalik
Zoltán Kutalik
CAChiara Auwerx
Chiara Auwerx
Telomeres represent repeated DNA sequences at the ends of chromosomes, which shorten with each cell division. Factors modulating telomere attrition and the health consequences thereof are not fully understood. To address this, we leveraged data from 326,363 unrelated UK Biobank participants of European ancestry and used linear regression and bidirectional univariable and multivariable Mendelian randomization (MR and MVMR) to elucidate the relationships between leukocyte telomere length (LTL) and 141 complex traits, including diseases, biomarkers, and lifestyle factors. We confirm that telomeres shorten with age and show a stronger decline in males than in females, which cannot be explained by hormonal or lifestyle differences. MR revealed 23 traits modulating LTL; e.g., smoking cessation and high educational attainment associated with longer LTL, while weekly alcohol intake, body mass index, urate levels, and female reproductive events, such as childbirth, associated with shorter LTL. We also identified 26 traits affected by LTL, with risk for cardiovascular, pulmonary, renal, and some autoimmune diseases being increased by short LTL, while longer LTL increased risk for other autoimmune conditions and cancers. Through MVMR, we show that LTL partially mediates the impact of educational attainment, body mass index, and female age at childbirth on lifespan. These results provide new insights into the biology of telomere regulation by shedding light on the modulators, consequences, and the mediatory role of telomere shortening, portraying an intricate relationship between LTL, diseases, lifestyle, and socio-economic factors.

1 January 2023 in Biology Methods and Protocols
Verified
Journal Article
Open access
PDF file
MBMarie-Claude Blatter
Marie-Claude Blatter
MZMonique Zahn-Zabal
Monique Zahn-Zabal
SMSamuel Moix
Samuel Moix
BPBéatrice Pichon
Béatrice Pichon
CDChristophe Dessimoz
Christophe Dessimoz
NGNatasha Glover
Natasha Glover
Evolution stands as a foundational pillar within modern biology, shaping our understanding of life. Studies related to evolution, for example constructing phylogenetic trees, are often carried out using DNA or protein sequences. These data, readily accessible from public databases, represent a treasure trove of resources that can be harnessed to create engaging activities with the public. At the heart of our project lies a collection of “stories” about evolution, each rooted in genuine scientific publications that furnish both biological context and supporting evidence. These narratives serve as the focal point of our LightOfEvolution.org website. Each story is accompanied by a dedicated “Your Turn to Play” section. Within this section, we furnish user-friendly activities and step-by-step guidelines, equipping visitors with the means to replicate analyses showcased in the highlighted publications. For example, the website OhMyGenes.org, relying on authentic scientific data, provides the capability to compute the proportion of shared genes across different species. Here, visitors can address the captivating question: “How many genes do we share with a banana?” To extend the educational reach, we have developed a series of modular activities, also related to the stories. These activities have been thoughtfully designed to be adaptable for face-to-face workshops held in classrooms or presented during public events. We aim to create stories and activities that resonate with participants, offering a tangible and enjoyable experience. By providing opportunities that reflect real-world scientific practices, we seek to offer participants valuable insights into the current workings of scientists “in the light of evolution.”

11 October 2025 in bioRxiv
Verified
Preprint
Open access
SMSamuel Moix
Samuel Moix
MSMarie C Sadler
Marie C Sadler
ZKZoltán Kutalik
Zoltán Kutalik
Drugs targeting genes supported by human genetic evidence are more likely to succeed in clinical trials. While previous approaches have benchmarked individual methods such as genome-wide association studies (GWAS), rare variant burden testing, and quantitative trait locus (QTL)-informed Mendelian randomization, it remains unclear how best to integrate these signals for drug target discovery. Here, we compared gene-prioritization strategies across 30 complex traits, evaluating their ability to recover approved drug targets compiled into lenient and moderate gold-standard sets from six curated databases. Gene-level association scores from GWAS, expression QTL, protein QTL, and exome-based analyses were integrated using five unsupervised approaches. Predictive performance was assessed with area under the receiver operating characteristic curve (AUROC) and enrichment-based statistics. Across traits, GWAS alone ranked known drug targets on average ∼652 ranks (3.42%) above random expectation, and the minimum-rank-based integration strategy provided an improvement of further ∼558 positions (2.93%), achieving the best AUROC in 23 of 30 traits. When comparing genetic correlation and drug target overlap across trait pairs, we observed a significant positive association ( r = 0.193; p = 5.46 e −5), and cross-trait analyses further revealed that prioritization scores derived from related diseases could at times equal or even surpass a trait’s own performance. For instance, coronary artery disease data improved the prediction of stroke targets ( p = 0.004), while inflammatory bowel disease data enhanced the prioritization of chronic kidney disease targets ( p = 0.014). Taken together, these results demonstrate that integrating complementary genetic signals through a minimum-rank-based framework, combined with information from genetically related traits, systematically strengthens drug target identification across complex diseases.

6 July 2026 in Genome Medicine
Verified
Journal Article
Open access
PDF file
SMSamuel Moix
Samuel Moix
MSMarie C. Sadler
Marie C. Sadler
ZKZoltán Kutalik
Zoltán Kutalik
Background: Drugs targeting genes supported by human genetic evidence are more likely to succeed in clinical trials. While previous approaches have benchmarked individual methods such as genome-wide association studies (GWAS), rare variant burden testing, and quantitative trait locus (QTL)-informed Mendelian randomization, it remains unclear how best to integrate these signals for drug target discovery. Methods: We compared gene-prioritization strategies across 30 complex traits, evaluating their ability to recover approved drug targets compiled into lenient and moderate gold-standard sets from six curated databases. Gene-level association scores from GWAS, expression QTL, protein QTL, and exome-based analyses were integrated using five unsupervised approaches. Predictive performance was assessed with area under the receiver operating characteristic curve (AUROC) and enrichment-based statistics. Results: Across traits, GWAS alone ranked known drug targets on average $$\sim $$ 652 ranks (3.42%) above random expectation, and the minimum-rank-based integration strategy further improved performance by approximately $$\sim $$ 558 positions (2.93%), achieving the best AUROC in 23 of 30 traits. Genetic correlation and drug target overlap across trait pairs showed a significant positive association ( $$r = 0.193;\ p = 5.46e{-}5$$ ). Cross-trait analyses further revealed that prioritization scores derived from related diseases could at times equal or even surpass a trait’s own performance. For instance, coronary artery disease data improved the prediction of stroke targets ( $$p = 0.004$$ ), while inflammatory bowel disease data enhanced the prioritization of chronic kidney disease targets ( $$p = 0.014$$ ). Conclusions: These results demonstrate that using the strongest signal from complementary genetic prioritization methods, combined with information from genetically related traits, systematically strengthens drug target identification across complex diseases.